What is IPO Grey Market Premium (GMP)?

IPO Grey Market Premium (GMP) is an unofficial, over-the-counter premium over the issue price that dealers and investors pay prior to official listing on NSE/BSE.

How is estimated IPO listing price determined?

Estimated Listing Price = Cut-off / Issue Price + Current Grey Market Premium (GMP). For example, an issue price of ₹100 with ₹40 GMP yields an estimated listing price of ₹140 (+40%).

What is Kostak rate in an IPO?

Kostak rate is the fixed profit earned by selling an IPO application before allotment, irrespective of whether the application is allotted shares or not.

What is Subject to Sauda in IPO trading?

Subject to Sauda is an informal contract where payment is made only if the seller receives share allotment in the IPO.

Is IPO Grey Market Premium (GMP) regulated by SEBI?

No. Grey Market transactions are non-exchange over-the-counter commitments and are not officially regulated or endorsed by SEBI. Investors should treat GMP as an informal sentiment indicator.

What is the current subscription status of Concord Biotech Limited IPO?

Concord Biotech Limited IPO has received a total subscription of 26.13 times overall.

IPO GreyPremiumLIVE

Grey Market Intelligence

Concord Biotech Limited

ListedMainboard

Pharmaceuticals & Biotechnology · NSE / BSE

Incorporated in 1984, Concord Biotech Limited is an India-based biopharmaceutical company and a leading global developer and manufacturer of fermentation-based APIs, specializing in immunosuppressants and oncology. The company has a strong global presence, supplying products to over 70 countries including the USA, India, Europe, and Japan. Concord Biotech manufactures Active Pharmaceutical Ingredients (APIs) through fermentation and semi-synthetic processes, along with finished formulations. Starting with a single product, the company has expanded to offer a broad spectrum of biopharma solutions, establishing itself as a key player in the global API market.

Price Band

₹705 – ₹741

Issue Size

₹1551 Cr

Lot Size

20 shares

GMP

₹125

+16.9%

Est. Listing

₹866

at current GMP

Subscribed

26.13x

overall

Open

4 Aug 2023

8 Aug 2023

Allotment

14 Aug 2023

Refund

15 Aug 2023

Demat Credit

16 Aug 2023

Listing

18 Aug 2023

Last updated 12 days ago

Overview Live GMP Subscription Status Allotment Status Filing Documents

Overall Subscription

26.13x

Total Demand

QIB Multiplier

71.12x

Institutions & Funds

NII / HNI

17.86x

High Net-Worth

Retail (RII)

3.97x

Individual Bidders

Category-Wise Subscription Breakup

Live bidding breakdown by institutional, non-institutional, and retail investors

Total 26.13x

Category	Shares Offered	Shares Applied / Bid	Times Subscribed
QIB	3,979,901	283,064,540	71.12x
NIB	2,984,926	53,304,000	17.86x
HNIs(10L +)	1,989,951	40,368,000	20.29x
HNIs (2-10L)	994,976	12,936,000	13.00x
RETAIL	6,964,828	27,669,940	3.97x
EMPLOYEES	9,514	244,720	25.72x
Total	16,924,096	417,587,200	26.13x

Application-Wise Breakup

Total unique applications received across retail and HNI tranches

Apps 4.47x

Category	Applications Reserved	Applications Received	Times Subscribed
Retail (RII)	366,296	1,454,195	3.97x
HNIs (10L +)	2,343	41,846	17.86x
HNIs (2-10L)	11,213	200,264	17.86x
Total Applications	379,852	1,696,305	4.47x

Day-Wise Subscription Progress

Track continuous institutional and retail bidding order books for all active issues on the ipo live subscription feed.

About Concord Biotech Limited Public Issue & Market Profile

Concord Biotech Limited is bringing an initial public offering (IPO) in the Pharmaceuticals & Biotechnology sector with an aggregate issue size of ₹1,551 Crores. The shares are offered at a price band of ₹705 to ₹741 per equity share on NSE and BSE. Currently, market analysts recommend evaluating the company's financial valuation, price-to-earnings (P/E) multiple, and peer comparison prior to submitting bids.

Bidding & Quota Instructions:

The public offer consists of a fresh issue and offer-for-sale structured under SEBI regulations. Bidding is open to Qualified Institutional Buyers (QIB), Non-Institutional Bidders (NII/HNI), and Retail Individual Investors (RII). Applications can be submitted online using ASBA or UPI mandate through certified stock brokers and net banking portals.

Allotment Reconciliation Schedule:

Following the close of bidding on 2023-08-08, the basis of allotment is scheduled to be finalized on 2023-08-14. Investors can verify their application status online by submitting their PAN card number, Application Number, or DP Client ID on the registrar's official portal (Link Intime India Private Limited) or the BSE allotment checking window.

Frequently Asked Questions

What is Concord Biotech Limited IPO GMP today?

The latest Grey Market Premium (GMP) for Concord Biotech Limited IPO is ₹125 per equity share. Based on the upper price band of ₹705 to ₹741 per equity share, the estimated listing price is ₹866 (+16.9% expected listing gain).

What is the expected profit per lot for Concord Biotech Limited IPO?

With a lot size of 20 shares and current GMP of ₹125, the expected profit per application lot is approx ₹2,500 (+16.9% gain). Minimum application cost is approx ₹14,820.

What is the issue size and price band for Concord Biotech Limited IPO?

The Concord Biotech Limited IPO aggregate issue size is ₹1,551 Crores with an equity price band set at ₹705 to ₹741 per equity share. The retail lot size is 20 shares requiring a minimum capital outlay of approx. ₹14,820.

How can I check Concord Biotech Limited IPO live subscription demand?

Live subscription figures are compiled real-time from the NSE and BSE bidding engines. Currently, overall subscription is 26.13x (Retail: 3.97x, QIB: 71.12x, NII: 17.86x). You can track live multiples directly on our dedicated subscription page.

Where and when will Concord Biotech Limited IPO allotment status be published?

The basis of allotment will be published on the official registrar portal (Link Intime India Private Limited) and the BSE status verification website on or around 2023-08-14. Investors can verify status using PAN card or application number.

When is the listing date for Concord Biotech Limited IPO?

Concord Biotech Limited shares are scheduled to list on NSE and BSE on 2023-08-18.